Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary
Journal article published in 2024 by
Antonio González-Martín,
Bhavana Pothuri,
Ignace Vergote,
Whitney Graybill,
Domenica Lorusso,
Colleen C. McCormick,
Gilles Freyer,
Floor Backes,
Florian Heitz,
Andrés Redondo,
Richard G. Moore,
Christof Vulsteke 
,
Roisin E. O'Cearbhaill,
Izabela A. Malinowska,
Luda Shtessel
and other authors.
,
Roisin E. O'Cearbhaill,
Izabela A. Malinowska,
Luda Shtessel
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 